Collaborators

Invenra, located at Element Labs in Madison, Wisconsin, specializes in the discovery, development, and production of precisely engineered monoclonal and bispecific antibodies. These antibodies are designed to bind specific targets and trigger various mechanisms of action through a wide range of modalities. Invenra’s team of over 60 highly skilled professionals has developed a leading platform for the discovery, expression, characterization, scale-up, and production of antibody-based therapies for a variety of human diseases, including cancer and immunology.

Precision Cancer Treatment: Driven by Antibodies

Cutting-edge techniques for imaging, diagnosing, and treating cancer are increasingly driven by antibodies due to their ability to be precisely engineered to target cancer cells. Whether pinpointing a tumor’s location, triggering the innate immune system to destroy cancer cells, or delivering a tumor-killing radio or chemical payload, antibodies are key to achieving maximum therapeutic precision while minimizing off-target effects.

Invenra: Innovating Antibody-Based Theranostics in Two Ways

1. The Best Antibody Platform – from Discovery to Production Invenra’s B-Body® Platform supports every stage of the process, from lead molecule screening and cell line development to scale-up and GMP production. The platform is distinguished by its unmatched antibody yield, broad biophysical compatibility, and proven performance across a wide range of development stages.
2. Bispecific Antibodies for Engineered Precision Therapy By combining two (or more) independent binding arms into engineered molecules, the B-Body Platform enables novel therapeutic approaches to cancer and other diseases (including autoimmune and infectious diseases). This includes the ability to target multiple tumor antigens for increased target affinity while sparing non-cancerous tissue. Additionally, it allows for the introduction of novel modes of action, fine-tuning target affinity, and the recruitment of additional therapeutic agents directly to the disease site.

Invenra B-Body Molecules: Advancing to the Clinic

Invenra has established partnerships with biotech and pharma researchers to advance B-Body Therapeutics into clinical trials for a variety of indications, including neuroblastoma, lung cancer, and other malignancies. Thanks to its broad-based performance, low immunogenicity, and high yield, Invenra’s B-Body Platform is rapidly becoming the preferred choice for cancer therapeutics.

Contact Us for More Information

BD@invenra.com or 608-441-8319